The Clinical and Economic Impact of Universal CMV Screening in Newborns

By Danélia Botes

April 11, 2024


Universal screening for congenital cytomegalovirus (CMV) for newborns has been a topic of considerable debate in medical circles. With the potential to identify congenital CMV infections early, the question arises: does the clinical benefit justify the cost? This article examines the implications of adding universal CMV screening to the Québec newborn screening program, reflecting on clinical outcomes and healthcare expenditure.

Understanding CMV and Its Consequences

CMV, a prevalent virus within the herpesviridae family, can cause congenital infections with variable outcomes. In Canada, the birth prevalence of congenital CMV (cCMV) is around 0.5%. While most infected newborns appear asymptomatic, a minority may suffer from severe neurodevelopmental issues, sensorineural hearing loss, or even mortality.

The Case for Universal Screening

The current method of screening in Québec captures only a fraction of cCMV cases by means of polymerase chain reaction (PCR) test on saliva. A rapid review and narrative synthesis of existing literature, alongside expert consultations, have highlighted the potential of universal screening. PCR tests on saliva have shown promise, albeit with concerns over false positives and false negatives.

Weighing Clinical Benefits Against Costs

The clinical dimension of universal CMV screening is compelling, particularly for early intervention in hearing loss. However, the economic dimension cannot be overlooked. Limited evidence suggests that universal screening may be cost-effective, potentially leading to savings or cost-neutrality in public healthcare spending.

Ethical Considerations and Healthcare Equity

Universal screening could reduce inequities by aiding vulnerable populations. Conversely, it may also inadvertently increase stigma or delay treatment for other conditions. The ethical landscape is complex, necessitating careful consideration.

Operational Challenges and Recommendations

Implementing universal CMV screening would necessitate significant changes in sample collection and processing. Given the current healthcare labour shortages, the anticipated benefits may not be fully realised. Consequently, the Institut national d’excellence en santé et en services sociaux (INESSS) does not recommend adding cCMV screening to Québec’s newborn screening program at this time. Instead, a focus on public education about CMV prevention is advised.


While universal CMV screening presents clear clinical advantages, its cost-effectiveness and impact on healthcare equity and operations must be scrutinised. As the healthcare landscape evolves, so too may the recommendations on universal CMV screening, pending further evidence.

Reference url

Recent Posts

Epidemic intelligence

How User-Centered Perspectives Foster Innovation in Digital Health Surveillance for Epidemic Intelligence in Europe

🌍🔬European Epidemic Intelligence: Overcoming Challenges in Data Reporting and Surveillance 📊🦠

Effective epidemic intelligence is crucial for managing public health threats. Discover the challenges faced by practitioners and the proposed improvements to enhance data reporting and surveillance systems. Let’s work together to build a healthier future! 💪

#EpidemicIntelligence #PublicHealth #DataReporting #Surveillance #HealthcareInnovation #AIConsulting #LifeSciences #ValueBasedHealthcare #MarketAccess

Join the conversation and share your thoughts on improving epidemic intelligence! 💬

Quality-Adjusted Life Year (QALY)

Quality-Adjusted Life Year (QALY) in Modern Healthcare Decision-Making

🔍 Understanding QALYs in Healthcare Decision-Making 🔍

The recent passage of HR 485 has sparked a debate on the use of Quality-Adjusted Life Years (QALYs) in healthcare. QALYs are crucial for measuring the effectiveness of medical treatments, ensuring fair treatment for all. Learn about their importance and the potential implications of HR 485.

#Healthcare #MedicalResearch #QALYs #HealthPolicy #HealthEconomics #MedicalInnovation


Patient Empowerment in Their Pockets: AI Chatbots in Healthcare

🧠 Unlocking the Power of AI: Chatbots Simplifying Pathology Reports 📊 Explore how artificial intelligence is transforming patient understanding of complex medical data. Learn more about the potential impact on healthcare communication and accessibility. #HealthTech #PatientCare #AIInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.



1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA



© 2024 Syenza™. All rights reserved.